公司資料
Coherus BioSciences, Inc. 股價、新聞與催化劑
- 股票代碼:
- CHRS
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.15 USD (-4.17%)
收盤價
最後更新: 2026年8月17日
234M USD
市值
股價為何變動
The latest monitored company update is “Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights.” The corresponding closing-price reaction is not yet available.
公司概覽
Immuno-Oncology Portfolio
Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI.
Casdozokitug
Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in first-line hepatocellular carcinoma. The program targets IL-27-mediated immune suppression and is being evaluated in a randomized Phase 2 trial.
Tagmokitug
Tagmokitug is a CCR8-directed antibody designed to selectively deplete regulatory T cells in tumors. Combination studies with toripalimab span head and neck, upper gastrointestinal, esophageal and colorectal cancers.
未來催化劑
- Initial data from the first-line HCC Phase 2 study of casdozokitug around mid-2026.
- Initial Phase 1b tagmokitug combination data in second-line head and neck and upper gastrointestinal cancers in mid-2026.
- First tagmokitug combination data in esophageal squamous-cell carcinoma in the second half of 2026.
- Initial tagmokitug combination data in late-line colorectal cancer in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。